|
|
XTL BIopharmaceuticals Limited - Comparative Business Analysis Snapshot
Business Description
XTL BIopharmaceuticals Limited. The Group's principal activity is the acquisition, development and commercialization of therapeutics for the treatment of neurophatic pain and, Hepatitis C. The Company is a development stage biotechnology company. It does not yet have any product sales and expects to consume cash until products are commercialised. The Company's shares are traded on the London, New York and Tel Aviv Stock Exchange.
Competitor Analysis
This analysis compares XTL BIopharmaceuticals Limited with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
